Develops and commercializes prescription medicines for gastrointestinal distress in humans and animals. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 28% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 4 years, sales grew about 28% a year on average.
Sales run at $11.5M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 46 buys and 9 sells. Management buying with its own money is usually read as a good sign.
A loss of $53.4M against $11.5M in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.31. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, JAGX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: JAGX is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (51/100) says the stock isn’t cheap.